CENTER FOR DERMAL RESEARCH

CDR SEMINAR SERIES

Dr. Sam Shefer

CEO of Salvona Technologies, LLC

June 2nd, 2014

"Nanotechnology Delivery Systems To Treat Acne - Practical Approach"

BIOGRAPHY:

Dr. Sam Shefer is the founder and CEO of Salvona Technologies LLC since 1999. The company's focus has been on developing and commercializing innovative smart encapsulation technologies used to control the delivery of active pharmaceutical ingredients for topical applications. Sam has earned over 80 patents and won the Nano 50 Award from "NASA Tech Brief" for the top 50 technologies that have significant impact on the business.

Sam Shefer earned a PhD in Biology and Chemical Engineering and a post-doctoral fellowship with Dr. Robert Langer at Massachusetts Institute of Technology, where he developed an implantable bio-reactor.

Sam gained industrial experience with W R Grace, in biomedical engineering and worked for IFF on consumer products. Over the last 14 years, in Salvona, he developed unique systems such as wireless endoscopy, soluble patches and multiple solutions for topical diseases such as acne and atopic dermatitis, which are based on nano and micro sphere technologies. These technologies gained commercial success and are available worldwide.

ABSTRACT:

The unique features of submicron spheres, small enough to potentially penetrate into the follicles and deeper layers of the skin, and release drugs where they are needed the most; offer major promise to the dermatology and cosmetics industries. The presentation will describe the process of commercializing technology-based products to treat acne.

The technology principle is cutting edge and fascinating academically, however the transfer of the concept into commercial success has several hitches. Large-scale production; regulatory restrictions in different countries; and the changing global economy are among the major factors playing a role in the process and affect the successful outcome.

Delivery systems can effect the formulation, stability and the esthetic of the end product. However, when done successfully it can be used to reduce the dosages thereby allowing to offer products with pharmaceutical efficacy but with cosmetic dosage, which is cost effective.

LOCATION:	Life Sciences Building Rutgers - The State University of New Jersey, 145 Bevier Road, Piscataway, New Jersey 08854, New Jersey Center for Biomaterials Suite - Conference Room 102
TIME:	5:30 PM
HOST:	Bozena B. Michniak-Kohn, Ph.D., M.R.Pharm.S. Director, Center for Dermal Rsearch, Professor of Pharmaceutics, Ernest Mario School of Pharmacy